firuglipel

G protein-coupled receptor 119 agonist for treatment of type 2 diabetes

Also Known As:

4(5-((1-(S))-1-(4-(cyclopropanecarbonyl)phenoxy)propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-(N)-((2-(S))-1-hydroxypropan-2-yl)benzamide; DS-8500a

Networked: 8 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shiosakai, Kazuhito: 5 articles (01/2019 - 01/2017)
2.	Taguchi, Takashi: 5 articles (01/2019 - 01/2017)
3.	Matsumoto, Koji: 3 articles (12/2019 - 01/2018)
4.	Terauchi, Yasuo: 3 articles (01/2019 - 01/2018)
5.	Watada, Hirotaka: 3 articles (01/2019 - 01/2018)
6.	Yamada, Yuichiro: 3 articles (01/2019 - 01/2018)
7.	Nakatsuka, Yasuhiko: 3 articles (11/2018 - 01/2017)
8.	Washio, Takuo: 3 articles (11/2018 - 01/2017)
9.	Inagaki, Nobuya: 2 articles (12/2019 - 01/2017)
10.	Yoshitomi, Tomomi: 2 articles (12/2018 - 01/2018)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 01/01/2018 - "Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study." 01/01/2017 - "In this double-blind, parallel-group, phase II study, 99 Japanese patients with type 2 diabetes were randomized to receive placebo, or DS-8500a 10 mg or 75 mg once daily for 28 days. " 01/01/2017 - "The study objective was to assess the efficacy and safety of DS-8500a in Japanese patients with type 2 diabetes. " 12/01/2018 - "DS-8500a is a useful compound among GPR119 agonists that can maximize the potential benefit of GPR119 in type 2 diabetes." 01/01/2018 - "[The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus]."
2.	Glucose Intolerance 12/01/2019 - "During the 8-week study, the treatment of mice with DS-8500a delayed and attenuated the progression of glucose intolerance compared with mice under dietary restriction alone. "
3.	Hypoglycemia (Reactive Hypoglycemia) 01/01/2018 - "Two cases of clinically relevant drug-related hypoglycemia occurred in the DS-8500a 50-mg group. " 01/01/2017 - "Both doses of DS-8500a were well tolerated without significant treatment-related adverse events, hypoglycemia, or discontinuations due to adverse events. "
4.	Chronic Kidney Failure (Chronic Renal Failure) 08/01/2018 - "DS-8500a exposure in the mild hepatic impairment and mild to severe renal impairment groups was similar to that in the corresponding normal hepatic and renal function groups, but dose adjustments may be required in those with moderate hepatic impairment and ESRD. "
5.	Insulin Resistance 01/01/2019 - "DS-8500a enhanced insulin secretory capacity, but not insulin sensitivity."

Related Drugs and Biologics

1.	GTP-Binding Proteins (G-Protein)
2.	Lipids
3.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
4.	Insulin (Novolin)
5.	Glucose (Dextrose)
6.	Sitagliptin Phosphate (Januvia)

Related Therapies and Procedures

1.	Glycemic Control
2.	Diet Therapy (Therapy, Diet)
3.	Therapeutics